Safety assessment of probiotics for human use

Gut Microbes

Volumn 1, Issue 3, 2010, Pages 164-185

  Sanders, Mary Ellen ^a   Akkermans, Louis M A ^b   Haller, Dirk ^c   Hammerman, Cathy ^d   Heimbach, James ^e   Hörmannsperger, Gabriele ^c   Huys, Geert ^f   Levy, Dan D ^g   Lutgendorff, Femke ^b   Mack, David ^h   Phothirath, Phoukham ⁱ   Solano Aguilar, Gloria ^j   Vaughan, Elaine ^k  

^a DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

^e JHeimbach LLC   (United States)

^f GHENT UNIVERSITY   (Belgium)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ NESTLÉ RESEARCH CENTER   (Switzerland)

^j BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^k UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

more..

Author keywords

Antibiotic resistance; Bifidobacterium; FDA; Health canada; Lactobacillus; Probiotic; PROSAFE; QPS; Safety

Indexed keywords

NITRIC OXIDE; PROBIOTIC AGENT; VIRULENCE FACTOR;

ACUTE PANCREATITIS; ANTIBIOTIC RESISTANCE; BIFIDOBACTERIUM; CRITICALLY ILL PATIENT; CROHN DISEASE; DRUG ACTIVITY; DRUG SAFETY; GENE SEQUENCE; GENE TRANSFER; GENETIC STABILITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFECTION RISK; INTESTINE FLORA; INTESTINE ISCHEMIA; LACTOBACILLUS; LACTOBACILLUS RHAMNOSUS; MICROBIAL COMMUNITY; NONHUMAN; PATHOGENICITY; POPULATION; PREMATURITY; REGULATORY T LYMPHOCYTE; REPRODUCTION; REVIEW; RISK FACTOR; SIDE EFFECT; ULCERATIVE COLITIS; ANIMAL; BACTERIUM; CHEMISTRY; DRUG THERAPY; FOOD SAFETY; GENETICS; INTESTINE; MICROBIOLOGY; PRODUCT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIFIDOBACTERIUM; LACTOBACILLUS;

ANIMALS; BACTERIA; CONSUMER PRODUCT SAFETY; DRUG THERAPY; FOOD SAFETY; HUMANS; INTESTINES; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954820449     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.1.3.12127     Document Type: Review

References (207)

1. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. 2001; (Accessed 2009, at http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf).
2. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005; 24:125-6.
3. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115:178-81.
4. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, species identification and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006; 42:35-44.
5. Bernardeau M, Guguen M, Vernoux JP. Beneficial lactobacilli in food and feed: long-term use, biodiversity and proposals for specific and realistic safety assessments. FEMS Microbiol Rev 2006; 30:487-513.
6. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:651-9.
7. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19:16-20.
8. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28:1159-60.
9. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5:290-2.
10. Spinosa MR, Braccini T, Ricca E, et al. On the fate of ingested Bacillus spores. Res Microbiol 2000; 151:361-8.
11. Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998; 36:325-6.
12. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004; 38:457-8.
13. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256-64.
14. Vesterlund S, Vankerckhoven V, Saxelin M, Goossens H, Salminen S, Ouwehand AC. Safety assessment of Lactobacillus strains: presence of putative risk factors in faecal, blood and probiotic isolates. Int J Food Microbiol 2007; 116:325-31.
15. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36:775-80.
16. Salminen MK, Tynkkynen S, Rautelin H, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35:1155-60.
17. Bernardeau M, Vernoux JP, Henri-Dubernet S, Gueguen M. Safety assessment of dairy microorganisms: the Lactobacillus genus. Int J Food Microbiol 2008; 126:278-85.
18. Snydman DR. The safety of probiotics. Clin Infect Dis 2008; 46:104-11.
19. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7:688-93.
20. Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol 2001; 21:264-71.
21. Hoffmann M, Rath E, Holzlwimmer G, et al. Lactobacillus reuteri 100-23 transiently activates intestinal epithelial cells of mice that have a complex microbiota during early stages of colonization. J Nutr 2008; 138:1684-91.
22. Mater DD, Langella P, Corthier G, Flores MJ. A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive transit in mice. J Mol Microbiol Biotechnol 2008; 14:123-7.
23. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-23.
24. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50:2075-82.
25. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361:1869-71.
26. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGFbeta-bearing regulatory cells. J Immunol 2005; 174:3237-46.
27. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock 2007; 28:384-93.
28. Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003; 31:598-607.
29. Lievin V, Peiffer I, Hudault S, et al. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000; 47:646-52.
30. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52:988-97.
31. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PS, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 2005; 73:5183-8.
32. Yan F, Polk DB. Probiotic bacterium prevents cytokineinduced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277:50959-65.
33. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007; 132:562-75.
34. Petrof EO, Kojima K, Ropeleski MJ, et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004; 127:1474-87.
35. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000; 68:5998-6004.
36. Hart AL, Lammers K, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53:1602-9.
37. Galdeano CM, de Moreno de Le-Blanc A, Vinderola G, Bonet ME, Perdigon G. Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin Vaccine Immunol 2007; 14:485-92.
38. Sugawara G, Nagino M, Nishio H, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006; 244:706-14.
39. Gollin G, Marks C, Marks WH. Intestinal fatty acid binding protein in serum and urine reflects early ischemic injury to the small bowel. Surgery 1993; 113:545-51.
40. Besselink MG, van Santvoort HC, Renooij W, et al. Intestinal Barrier Dysfunction in a Randomized Trial of a Specific Probiotic Composition in Acute Pancreatitis. Ann Surg 2009.
41. Lutgendorff F, Nijmeijer RM, Sandstrom PA, et al. Probiotics prevent intestinal barrier dysfunction in acute pancreatitis in rats via induction of ileal mucosal glutathione biosynthesis. PLoS ONE 2009; 4:4512.
42. Lutgendorff F, Trulsson LM, van Minnen LP, et al. Probiotics enhance pancreatic glutathione biosynthesis and reduce oxidative stress in experimental acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2008; 295:1111-21.
43. Ammori BJ. Role of the gut in the course of severe acute pancreatitis. Pancreas 2003; 26:122-9.
44. Siriwardena AK, Mason JM, Balachandra S, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut 2007; 56:1439-44.
45. Voltan S, Martines D, Elli M, et al. Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa. Gastroenterology 2008; 135:1216-27.
46. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemiareperfusion injury, inflammation and shock. Cardiovasc Res 2005; 65:772-81.
47. The use of probiotics for patients in hospitals. A benefit and risk assessment. Opinion of the Steering Committee of the Norwegian Scientific Committee for Food Safety. 2009; (Accessed 2009, at http://www.vkm.no/dav/009488e0b8.pdf).
48. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; 6873.
49. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006; 4826.
50. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 6634.
51. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-9.
52. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-14.
53. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005; 22:721-8.
54. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 5573.
55. Tsuda Y, Yoshimatsu Y, Aoki H, et al. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007; 42:1306-11.
56. Huynh HQ, deBruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009; 15:760-8.
57. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104:437-43.
58. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:1202-9.
59. Farina C, Arosio M, Mangia M, Moioli F. Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 2001; 33:251-2.
60. Palmer C, Bik EM, Digiulio DB, Relman DA, Brown PO. Development of the Human Infant Intestinal Microbiota. PLoS Biol 2007; 5:177.
61. Gewolb IH, Schwalbe RS, Taciak VL, Harrison TS, Panigrahi P. Stool microflora in extremely low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1999; 80:167-73.
62. Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. Acta Paediatr Suppl 2003; 91:48-55.
63. Meng D, Newburg DS, Young C, et al. Bacterial symbionts induce a FUT2-dependent fucosylated niche on colonic epithelium via ERK and JNK signaling. Am J Physiol Gastrointest Liver Physiol 2007; 293:780-7.
64. Bates JM, Mittge E, Kuhlman J, Baden KN, Cheesman SE, Guillemin K. Distinct signals from the microbiota promote different aspects of zebrafish gut differentiation. Dev Biol 2006; 297:374-86.
65. Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007; 119:192-8.
66. Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004; 79:261-7.
67. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in Southern Finland, 1989-1992. Clin Infect Dis 1996; 22:564-6.
68. Hata D, Yoshida A, Ohkubo H, et al. Meningitis caused by Bifidobacterium in an infant. Pediatr Infect Dis J 1988; 7:669-71.
69. Barton LL, Rider ED, Coen RW. Bacteremic infection with Pediococcus: vancomycin-resistant opportunist. Pediatrics 2001; 107:775-6.
70. Honeycutt TC, El Khashab M, Wardrop RM, 3rd, et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 2007; 8:452-8.
71. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115:5-9.
72. Vendt N, Grunberg H, Tuure T, et al. Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: doubleblind, randomized trial. J Hum Nutr Diet 2006; 19:51-8.
73. Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula and baby foods (II). 2007; (Accessed 2009, at http://www.vkm.no/dav/63bb45d3eb.pdf).
74. Abrahamsson TR, Jakobsson T, Bottcher MF, et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2007; 119:1174-80.
75. Chouraqui JP, Grathwohl D, Labaune JM, et al. Assessment of the safety, tolerance and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. Am J Clin Nutr 2008; 87:1365-73.
76. Gibson RA, Barclay D, Marshall H, Moulin J, Maire JC, Makrides M. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomised controlled trial. Br J Nutr 2009; 101:1706-13.
77. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-9.
78. Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics 2008; 122:8-12.
79. Puccio G, Cajozzo C, Meli F, Rochat F, Grathwohl D, Steenhout P. Clinical evaluation of a new starter formula for infants containing live Bifidobacterium longum BL999 and prebiotics. Nutrition 2007; 23:1-8.
80. Vlieger AM, Robroch A, van Buuren S, et al. Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial. Br J Nutr 2009; 102:869-75.
81. JW D, K W, PN B, et al. Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis ssp. lactis HN019 in human infants aged 0 to 2 years. Int Dairy J 2009; 19:149-54.
82. Wickens K, Black P, Stanley T, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2008; 122:788-94.
83. Stolley H, Droese W. Lactic acid in milk formula, the influence on absorption of nutrients and the influence on the metabolism in young babies. Acta Paediatr Scand 1971; 60:367-8.
84. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol 2002; 68:219-26.
85. Schultz M, Gottl C, Young RJ, Iwen P, Vanderhoof JA. Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization. J Pediatr Gastroenterol Nutr 2004; 38:293-7.
86. Gueimonde M, Kalliomaki M, Isolauri E, Salminen S. Probiotic intervention in neonates-will permanent colonization ensue? J Pediatr Gastroenterol Nutr 2006; 42:604-6.
87. Strachan DP. Hay fever, hygiene and household size. Bmj 1989; 299:1259-60.
88. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2007; 119:1019-21.
89. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008; 121:850-6.
90. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007; 119:184-91.
91. Prescott SL, Wiltschut J, Taylor A, et al. Early markers of allergic disease in a primary prevention study using probiotics: 2.5-year follow-up phase. Allergy 2008; 63:1481-90.
92. Sakata S, Tonooka T, Ishizeki S, et al. Cultureindependent analysis of fecal microbiota in infants, with special reference to Bifidobacterium species. FEMS Microbiol Lett 2005; 243:417-23.
93. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147:192-6.
94. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122:693-700.
95. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115:1-4.
96. Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007; 369:1614-20.
97. Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002; 82:103-8.
98. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci USA 2002; 99:15451-5.
99. Wagner RD. Effects of microbiota on GI health: gnotobiotic research. Adv Exp Med Biol 2008; 635:41-56.
100. Hormannsperger G, Haller D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: Clinical relevance in the context of inflammatory bowel disease. Int J Med Microbiol 2009.
101. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6:306-14.
102. Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 2006; 4:413.
103. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002; (Accessed 2009, at http://http.fao.org/es/esn/food/wgreport2.pdf).
104. Saarela M, Mogensen G, Fonden R, Matto J, MattilaSandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000; 84:197-215.
105. Vankerckhoven V, Huys G, Vancanneyt M, et al. Biosafety assessment of probiotics used for human consumption: recommendations from the EU-PROSAFE project. Trends in food science & technology 2008; 19:102-14.
106. Huys G, Vancanneyt M, D'Haene K, Vankerckhoven V, Goossens H, Swings J. Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res Microbiol 2006; 157:803-10.
107. Masco L, Huys G, De Brandt E, Temmerman R, Swings J. Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol 2005; 102:221-30.
108. Temmerman R, Scheirlinck I, Huys G, Swings J. Culture-independent analysis of probiotic products by denaturing gradient gel electrophoresis. Appl Environ Microbiol 2003; 69:220-6.
109. Green DH, Wakeley PR, Page A, et al. Characterization of two Bacillus probiotics. Appl Environ Microbiol 1999; 65:4288-91.
110. Duc le H, Hong HA, Barbosa TM, Henriques AO, Cutting SM. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004; 70:2161-71.
111. Mohania D, Nagpal R, Kumar M, et al. Molecular approaches for identification and characterization of lactic acid bacteria. J Dig Dis 2008; 9:190-8.
112. Collado MC, Moreno Y, Cobo JM, Hernandez M. Microbiological evaluation and molecular characterization of bifidobacteria strains in commercial fermented milks. Eur Food Res Technol 2006; 222:112-7.
113. Coudeyras S, Marchandin H, Fajon C, Forestier C. Taxonomic and strain-specific identification of the probiotic strain Lactobacillus rhamnosus 35 within the Lactobacillus casei group. Appl Environ Microbiol 2008; 74:2679-89.
114. Massi M, Vitali B, Federici F, Matteuzzi D, Brigidi P. Identification method based on PCR combined with automated ribotyping for tracking probiotic Lactobacillus strains colonizing the human gut and vagina. J Appl Microbiol 2004; 96:777-86.
115. Naser SM, Dawyndt P, Hoste B, et al. Identification of lactobacilli by pheS and rpoA gene sequence analyses. Int J Syst Evol Microbiol 2007; 57:2777-89.
116. Ventura M, van Sinderen D, Fitzgerald GF, Zink R. Insights into the tazonomy genetics and physiology of bifidobacteria. Antonia van Leeuwenhoek 2004; 86:205-23.
117. Rooney AP, Price NP, Ehrhardt C, Swezey JL, Bannan JD. Phylogeny and molecular taxonomy of the Bacillus subtilis species complex and description of Bacillus subtilis subsp. inaquosorum subsp. nov. Int J Syst Evol Microbiol 2009; 59:2429-36.
118. Lee YK, Ho PS, Low CS, Arvilommi H, Salminen S. Permanent colonization by Lactobacillus casei is hindered by the low rate of cell division in mouse gut. Appl Environ Microbiol 2004; 70:670-4.
119. Alander M, Satokari R, Korpela R, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999; 65:351-4.
120. Klarin B, Johansson ML, Molin G, Larsson A, Jeppsson B. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Crit Care 2005; 9:285-93.
121. Sorokulova I. Preclinical testing in the development of probiotics: a regulatory perspective with Bacillus strains as an example. Clin Infect Dis 2008; 46:92-5.
122. Klare I, Konstabel C, Muller-Bertling S, et al. Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci and Bifidobacteria. Appl Environ Microbiol 2005; 71:8982-6.
123. Klare I, Konstabel C, Werner G, et al. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother 2007; 59:900-12.
124. Kastner S, Perreten V, Bleuler H, Hugenschmidt G, Lacroix C, Meile L. Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food. Syst Appl Microbiol 2006; 29:145-55.
125. Masco L, Van Hoorde K, De Brandt E, Swings J, Huys G. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother 2006; 58:85-94.
126. Huys G, D'Haene K, Swings J. Genetic basis of tetracycline and minocycline resistance in potentially probiotic Lactobacillus plantarum strain CCUG 43738. Antimicrob Agents Chemother 2006; 50:1550-1.
127. van Hoek AHAM, Margolles A, Domig KJ, et al. Molecular assessment of erythromycin and tetracycline resistance genes in lactic acid bacteria and bifidobacteria and their relation to the phenotypic resistance. International Journal of Probiotics and Prebiotics 2008; 3:271-80.
128. Update of the criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance. 2008; (Accessed 2009, at http://www.efsa.europa.eu/cs/BlobServer/Guidance_of_Panel/feedap_op_ej732_tg_antimicrobial_resistance_en.pdf?ssbinary=true).
129. Jorgensen J. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline, M45-A Clinical and Laboratory Standards Institute 2006.
130. Agency Additional Correspondence Letter GRAS Notice No. GRN 000049. 2005; (Accessed 2009, at http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASListings/ucm154391.htm).
131. Vancanneyt M, Huys G, Lefebvre K, Vankerckhoven V, Goossens H, Swings J. Intraspecific genotypic characterization of Lactobacillus rhamnosus strains intended for probiotic use and isolates of human origin. Appl Environ Microbiol 2006; 72:5376-83.
132. van de Guchte M, Penaud S, Grimaldi C, et al. The complete genome sequence of Lactobacillus bulgaricus reveals extensive and ongoing reductive evolution. Proc Natl Acad Sci USA 2006; 103:9274-9.
133. Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89:1103-7.
134. Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74:123-7.
135. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003; 36:223-7.
136. Sharieff W, Bhutta Z, Schauer C, Tomlinson G, Zlotkin S. Micronutrients (including zinc) reduce diarrhoea in children: the Pakistan Sprinkles Diarrhoea Study. Arch Dis Child 2006; 91:573-9.
137. Asahara T, Takahashi M, Nomoto K, et al. Assessment of safety of lactobacillus strains based on resistance to host innate defense mechanisms. Clin Diagn Lab Immunol 2003; 10:169-73.
138. Franz CM, Muscholl-Silberhorn AB, Yousif NM, Vancanneyt M, Swings J, Holzapfel WH. Incidence of virulence factors and antibiotic resistance among Enterococci isolated from food. Appl Environ Microbiol 2001; 67:4385-9.
139. Eaton TJ, Gasson MJ. Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl Environ Microbiol 2001; 67:1628-35.
140. Ge J, Catt DM, Gregory RL. Streptococcus mutans surface alpha-enolase binds salivary mucin MG2 and human plasminogen. Infect Immun 2004; 72:6748-52.
141. Mack DR. D(-)-lactic acid-producing probiotics, D(-)lactic acidosis and infants. Can J Gastroenterol 2004; 18:671-5.
142. Hove H, Mortensen PB. Colonic lactate metabolism and D-lactic acidosis. Dig Dis Sci 1995; 40:320-30.
143. Walter J. Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. Appl Environ Microbiol 2008; 74:4985-96.
144. Bongaerts G, Bakkeren J, Severijnen R, et al. Lactobacilli and acidosis in children with short small bowel. J Pediatr Gastroenterol Nutr 2000; 30:288-93.
145. Connolly E, Abrahamsson T, Bjorksten B. Safety of D(-)-lactic acid producing bacteria in the human infant. J Pediatr Gastroenterol Nutr 2005; 41:489-92.
146. Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis. A review of clinical presentation, biochemical features and pathophysiologic mechanisms. Medicine (Baltimore) 1998; 77:73-82.
147. Hove H. Lactate and short chain fatty acid production in the human colon: implications for D-lactic acidosis, short-bowel syndrome, antibiotic-associated diarrhoea, colonic cancer and inflammatory bowel disease. Dan Med Bull 1998; 45:15-33.
148. Munakata S, Arakawa C, Kohira R, Fujita Y, Fuchigami T, Mugishima H. A case of D-lactic acid encephalopathy associated with use of probiotics. Brain Dev 2009.
149. Uchida H, Yamamoto H, Kisaki Y, Fujino J, Ishimaru Y, Ikeda H. D-lactic acidosis in short-bowel syndrome managed with antibiotics and probiotics. J Pediatr Surg 2004; 39:634-6.
150. MMWR. Leads from the MMWR. Scombroid fish poisoning-New Mexico, 1987. Jama 1988; 260:1217.
151. Straub BW, Kicherer M, Schilcher SM, Hammes WP. The formation of biogenic amines by fermentation organisms. Z Lebensm Unters Forsch 1995; 201:79-82.
152. Pessione E, Mazzoli R, Giuffrida MG, et al. A proteomic approach to studying biogenic amine producing lactic acid bacteria. Proteomics 2005; 5:687-98.
153. Hoa NT, Baccigalupi L, Huxham A, et al. Characterization of Bacillus species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders. Appl Environ Microbiol 2000; 66:5241-7.
154. Coeuret V, Gueguen M, Vernoux JP. Numbers and strains of lactobacilli in some probiotic products. Int J Food Microbiol 2004; 97:147-56.
155. Milazzo I, Speciale A, Musumeci R, Fazio D, Blandino G. Identification and antibiotic susceptibility of bacterial isolates from probiotic products available in Italy. New Microbiol 2006; 29:281-91.
156. Moneret-Vautrin DA, Morisset M, Cordebar V, Codreanu F, Kanny G. Probiotics may be unsafe in infants allergic to cow's milk. Allergy 2006; 61:507-8.
157. Lee TT, Morisset M, Astier C, et al. Contamination of probiotic preparations with milk allergens can cause anaphylaxis in children with cow's milk allergy. J Allergy Clin Immunol 2007; 119:746-7.
158. Momose H, Igarashi M, Era T, Fukuda Y, Yamada M, Ogasa K. Toxicological studies on Bifidobacterium longum BB536. Appl Pharmacol 1979; 17:881-7.
159. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73:465-70.
160. Lara-Villoslada F, Sierra S, Diaz-Ropero MP, Olivares M, Xaus J. Safety assessment of the human milkisolated probiotic Lactobacillus salivarius CECT5713. J Dairy Sci 2007; 90:3583-9.
161. Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials 2004; 5:183-91.
162. Gil L, Siems W, Mazurek B, et al. Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic Res 2006; 40:495-505.
163. Nielsen K, Duncan J. Animal Brucellosis. Boca Raton, FL: CRC Press, Inc 1990.
164. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:524-34.
165. Patti JM, Bremell T, Krajewska-Pietrasik D, et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun 1994; 62:152-61.
166. Beckerman KP, Rogers HW, Corbett JA, Schreiber RD, McDaniel ML, Unanue ER. Release of nitric oxide during the T cell-independent pathway of macrophage activation. Its role in resistance to Listeria monocytogenes. J Immunol 1993; 150:888-95.
167. Gras V, Bouffandeau B, Montravers PH, Lalau JD. Effect of metformin on survival rate in experimental sepsis. Diabetes Metab 2006; 32:147-50.
168. Vankerckhoven V, Moreillon P, Piu S, et al. Infectivity of Lactobacillus rhamnosus and Lactobacillus paracasei isolates in a rat model of experimental endocarditis. J Med Microbiol 2007; 56:1017-24.
169. Moreillon P, Que YA. Infective endocarditis. Lancet 2004; 363:139-49.
170. Moreillon P, Entenza JM, Francioli P, et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 1995; 63:4738-43.
171. Cohen MD. Bacterial host resistance models in the evaluation of immunotoxicity. Methods 2007; 41:20-30.
172. Vessie EL, Hirsch GM, Lee TD. Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice. Transpl Immunol 2005; 15:35-44.
173. Toxicological Principles for the Safety Assessment of Food Ingredients. Chapter IC.C.9.a: Guideline for Reproduction Studies. 2007; (Accessed 2009, at http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodIngredientsandPackaging/Redbook/default.htm).
174. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Detection Of Toxicity To Reproduction For Medicinal Products & Toxicity To Male Fertility. Harmonised Tripartite Guideline S5(R2). 2005; (Accessed 2009, at http://www.ich.org/LOB/media/MEDIA498.pdf).
175. Claud EC, Walker WA. Bacterial colonization, probiotics and necrotizing enterocolitis. J Clin Gastroenterol 2008; 42:46-52.
176. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008; 46:87-91.
177. Patterson JK, Lei XG, Miller DD. The pig as an experimental model for elucidating the mechanisms governing dietary influence on mineral absorption. Exp Biol Med (Maywood) 2008; 233:651-64.
178. Garthoff LH, Henderson GR, Sager AO, et al. The Autosow raised miniature swine as a model for assessing the effects of dietary soy trypsin inhibitor. Food Chem Toxicol 2002; 40:487-500.
179. Pang X, Hua X, Yang Q, et al. Inter-species transplantation of gut microbiota from human to pigs. Isme J 2007; 1:156-62.
180. Solano-Aguilar G, Dawson H, Restrepo M, Andrews K, Vinyard B, Urban JF Jr. Detection of Bifidobacterium animalis subsp. lactis (Bb12) in the intestine after feeding of sows and their piglets. Appl Environ Microbiol 2008; 74:6338-47.
181. Zhang W, Azevedo MS, Wen K, et al. Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs. Vaccine 2008; 26:3655-61.
182. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455:1109-13.
183. Collado MC, Grzeskowiak L, Salminen S. Probiotic strains and their combination inhibit in vitro adhesion of pathogens to pig intestinal mucosa. Curr Microbiol 2007; 55:260-5.
184. Solano-Aguilar G, Shea-Donohue T, Madden K, Dawson H, Ledbetter T, Urban JF Jr. The effect of human derived probiotic bacteria on the intestinal function of pigs. Edited by LC. Gasbarre. AAVP Symposium: New approaches in the study of animal parasites. Vet Parasitol 2004; 125:147-61.
185. Siggers RH, Siggers J, Boye M, et al. Early administration of probiotics alters bacterial colonization and limits diet-induced gut dysfunction and severity of necrotizing enterocolitis in preterm pigs. J Nutr 2008; 138:1437-44.
186. Harding SV, Fraser KG, Wykes LJ. Probiotics stimulate liver and plasma protein synthesis in piglets with dextran sulfate-induced colitis and macronutrient restriction. J Nutr 2008; 138:2129-35.
187. Piriou-Guzylack L, Salmon H. Membrane markers of the immune cells in swine: an update. Vet Res 2008; 39:54.
188. Porcine Immunology and Nutrition (PIN) database. (Accessed 2009, at http://www.ars.usda.gov/Services/docs.htm?docid=6065).
189. Chowdhury SR, King DE, Willing BP, et al. Transcriptome profiling of the small intestinal epithelium in germfree versus conventional piglets. BMC Genomics 2007; 8:215.
190. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6:280.
191. Dowd SE, Sun Y, Wolcott RD, Domingo A, Carroll JA. Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) for microbiome studies: bacterial diversity in the ileum of newly weaned Salmonella-infected pigs. Foodborne Pathog Dis 2008; 5:459-72.
192. Von Wright A. Regulating the safety of probiotics-the European approach. Curr Pharm Des 2005; 11:17-23.
193. Wassenaar TM, Klein G. Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. J Food Prot 2008; 71:1734-41.
194. Opinion of the Scientific Committee on Animal Nutrition on the criteria for assessing the safety of micro-organisms resistant to antibiotics of human clinical and veterinary importance. 2002; (Accessed 2009, at http://ec.europa.eu/food/fs/sc/scan/out108_en.pdf).
195. Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA-Opinion of the Scientific Committee 2007. (Accessed 2009, at http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1178667590178.htm).
196. On a generic approach to the safety assessment of micro-organisms used in feed/food and feed/food production. 2003; (Accessed 2009, at http://ec.europa.eu/food/fs/sc/scf/out178_en.pdf).
197. Probiotics. 2009; (Accessed 2009, at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licen-prod/monograph/mono_probioti-eng.php).
198. Guidance Document-The Use of Probiotic Microorganisms in Food. 2009; (Accessed 2009, at http://www.hc-sc.gc.ca/fn-an/legislation/guide-ld/probiotics_guidance-orientation_probiotiques-eng.php).
199. Sanders M. How do we know when something called "probiotic" is really a probiotic? A guideline for consumers and healthcare professionals. Functional Food Rev 2009; 1:3-12.
200. Immunomodulation by probiotics: efficacy and safety evaluation. 2005; (Accessed 2009, at http://www.rivm.nl/bibliotheek/rapporten/340320003.html).
201. Probiotics Task Force 2009; (Accessed 2009, at http://www.ilsi.org/Europe/Pages/TF_Probiotics.aspx).
202. Agency response letter: GRAS Notice No. GRN 000231. 2008; (Accessed 2009, at http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/GRASListings/ucm153907.htm).
203. Rayes N, Hansen S, Seehofer D, et al. Early enteral supply of fiber and Lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 2002; 18:609-15.
204. Rayes N, Seehofer D, Theruvath T, et al. Supply of preand probiotics reduces bacterial infection rates after liver transplantation-a randomized, doubleblind trial. Am J Transplant 2005; 5:125-30.
205. Kanazawa H, Nagino M, Kamiya S, et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg 2005; 390:104-13.
206. Rayes N, Seehofer D, Theruvath T, et al. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg 2007; 246:36-41.
207. Nomura T, Tsuchiya Y, Nashimoto A, et al. Probiotics reduce infectious complications after pancreaticoduodenectomy. Hepatogastroenterology 2007; 54:661-3.